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Background:  Aspirin (ASA) + clopidogrel is recommended for 3-6 months following transcather aortic valve replacement (TAVR). Many 
patients undergoing TAVR also have an indication for oral anticoagulation (OAC). Antithrombotic regimens prescribed to these patients 
have not been well studied.
methods:  Chart review of all patients undergoing TAVR at Brigham and Women’s Hospital between April 2009 and March 2014. 
Antithrombotic medications, comorbid conditions, and indications for OAC were assessed.
results:  Of 255 patients (mean age 81, 48% women), 169 (66%) had transfemoral TAVR. 131 (51%) patients had an indication for OAC 
pre-TAVR, 122 (48%) with atrial fibrillation (AF) and CHADS2 score >2, 6 (2%) with DVT/PE and 3 (1%) with other indications. Of these 
patients, 92 (70%) were on OAC prior to the procedure. Complete baseline and discharge antithrombotic use is shown in the table. Of 153 
patients with an indication for OAC post-TAVR (including 19 with new onset AF), 77 (51%) were bridged with parental anticoagulation after 
the procedure. Of 87 surviving patients on baseline OAC, 7 (8%) had OAC held after TAVR. Of 106 patients discharged on OAC, 89 (84%) 
were treated with ASA+OAC.
conclusion:  Antithrombotic regimens before and after TAVR are highly variable. At our institution, most patients on OAC prior to TAVR are 
discharged on ASA+OAC with half bridged with a parental anticoagulant. Prospective evaluation to determine the optimal antithrombotic 
regimen in this population is needed.
SAPT = ASA or P2Y12 antagonist, DAPT = ASA + P2Y12 antagonist, Triple = ASA + P2Y12 + OAC
Admission Antithrombotic Regimen Discharge Antithrombotic Regimen
SAPT DAPT OAC SAPT+OAC Triple Died TOTAL
None 4 16 0 4 1 5 30
SAPT 7 78 0 16 0 3 104
DAPT 1 21 0 4 1 2 29
OAC 0 1 2 21 7 2 33
SAPT+OAC 0 5 0 43 3 3 54
Triple 0 1 0 1 3 0 5
TOTAL 12 122 2 89 15 15 255
